Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Retatrutide and Tesofensine — mechanism, side effects, legal status, and pricing.
Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is in Phase 3 clinical trials for obesity and type 2 diabetes and has demonstrated the highest weight loss of any anti-obesity medication tested to date.
Tesofensine is a small-molecule triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) — NOT a peptide. Originally developed by NeuroSearch for Parkinson's and Alzheimer's disease (which it failed to benefit) and repositioned for obesity by Saniona. Not FDA-approved in the US.
Retatrutide
Tesofensine
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Retatrutide
Tesofensine
COA corpus from Disclosed Labs — independently tested batches only.
Retatrutide
413
COAs
99.7%
Avg purity
17
Labs
Tesofensine
15
COAs
99.4%
Avg purity
6
Labs
Phase 2 obesity trial (Jastreboff et al., NEJM 2023; PMID 37366315) demonstrated up to 24.2% body weight loss at 48 weeks at the 12 mg dose, exceeding both semaglutide and tirzepatide. A Phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023; PMID 37385280) showed robust HbA1c and weight reductions vs. placebo and dulaglutide. A Phase 2a MASLD trial (Sanyal et al., Nat Med 2024; PMID 38858523) demonstrated significant reductions in hepatic steatosis driven by glucagon receptor activation. Phase 3 TRIUMPH trials are ongoing (Eli Lilly), with results expected 2025–2026. Retatrutide is NOT FDA-approved as of April 2026 — it remains investigational.
Key references
Pivotal Phase 2 (Astrup et al., Lancet 2008, n=203, 24 weeks, Denmark) showed placebo-subtracted weight loss of 4.5%, 9.2%, and 10.6% at 0.25, 0.5, and 1.0 mg/day — roughly twice orlistat at 0.5 mg. (The Lancet issued an expression of concern about that trial in 2013.) Saniona's Mexico partner Medix ran a Phase 3 registration study that met its primary endpoint; Medix filed with COFEPRIS in May 2023 with supplemental data submitted in 2024. As of April 2026 a final Mexican approval decision is still pending — the commonly repeated '2022 Mexico approval' claim is inaccurate. Tesomet (tesofensine + metoprolol, intended to blunt cardiovascular signal) is in development for hypothalamic obesity and Prader-Willi syndrome.
Retatrutide and Tesofensine are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs